Growth Company/VC News EMEA


Search Highlights

This quarter’s successful placements in EMEA include:
  • Chief Medical Officer, vaccines developer, Austria
  • CEO, immuno-oncology & cell-therapy, Netherlands
  • Head M&A, outpatient services, Germany
  • Senior Finance Manager, animal health, Spain
  • Two Regional Heads of New Business, digital pathology software, DACH
  • Commercial Director, diagnostics products, UK
  • Non Executive Director, nanotechnology and drug particle engineering, Finland
  • Venture Partner UK and Venture Partner US CNS-focused VC fund, UK/ US
  • Principal, Life Science VC, Netherlands
  • Managing Director, bioscience incubator, UK
Newly opened projects include:
  • CEO, CNS
  • CSO, infectious diseases/ oncology
  • Head of European Sales, diagnostics
  • GM, Germany and Austria, CNS
  • Director Strategic Devt., radiopharmaceuticals
  • Chief Medical Officer, rare diseases
  • CFO, genetic diseases
  • Partner, Life Science consulting
  • VP Regulatory Affairs, immunology
  • CSO, microbiome


Areas of focus this quarter include but are not limited to:
  • Digital Health
  • CNS
  • Healthcare Services
  • Immuno-oncology
  • Cell Therapy
  • Diagnostics
  • Ophthalmology
  • Vaccines
  • Regenerative Medicine

Coulter News

  • Opening of new offices in Paris, Singapore and Sydney with 14 appointments worldwide
  • Extremely successful year with group sales up by 31%, financial year 2018/19
  • Promotion of Dr Kay Wardle to Managing Partner; over 20 years’ Life Science Search experience and extensive R&D expertise

Coulter Partners

  • Global market leader and largest global executive search firm dedicated to the Life Sciences and committed to delivering outstanding leadership
  • 85+ sector experts from a diversity of backgrounds working across 13 global offices.
  • Unrivalled network with the Life Sciences community with c. 260+ assignments each year across all segments of the industry.
  • Deep understanding of talent needs, business models, sector trends, scientific evolution, innovation and competitive positioning
  • Large proportion of search work for VC, PE and angel-funded biotech, medtech, and digital health companies
  • Working with 50+ VC and PE funds across US, UK and EMEA
  • 400+ senior leadership assignments for investor portfolio companies
  • Contact: